Planned Parenthood Cincinnati Region v. Bob Taft

444 F.3d 502, 2006 U.S. App. LEXIS 9207, 2006 WL 947302
Court of Appeals for the Sixth Circuit·Decided April 13, 2006·No. 04-4371·Published·Cited by 30 cases

Opinions

McKEAGUE, J., delivered the opinion of the court, in which ROGERS, J., joined.

MOORE, J. (p. 518-519), delivered a separate opinion concurring in part.

AMENDED OPINION

McKEAGUE, Circuit Judge.

This matter is before the court on Plaintiffs’ petition for panel rehearing. Upon consideration of the relevant briefs and the record, we vacate our prior opinion, Planned Parenthood v. Taft, 439 F.3d 304 (6th Cir.2006), and replace it with this amended opinion.

Plaintiffs challenge an Ohio statute which prohibits the off-label use of the abortion drug mifepristone (more commonly known as RU-486). The district court granted a preliminary injunction enjoining enforcement of the statute on two alternative grounds. The State timely filed an interlocutory appeal. For the following reasons, we hold that the district court’s primary holding was error, but affirm the reasoning of the district court’s alternative holding. Nevertheless, we vacate the district court’s order in part and remand for consideration of the appropriate scope of injunctive relief in light of the United States Supreme Court’s recent decision in Ayotte v. Planned Parenthood of Northern New England, — U.S. -, 126 S.Ct. 961, 163 L.Ed.2d 812 (2006).

I.

Until 2000 most first trimester abortions in this country were surgical abortions performed by vacuum aspiration or curettage. In September of 2000, the Food and Drug Administration (“FDA”) approved mifepristone, a pill used to induce an abortion without surgical intervention, for manufacture and use in the United States. This approval was based on clinical trials which involved the oral ingestion of 600 mg of mifepristone followed two days later by the oral ingestion of 0.4 mg of misoprostol.1 Upon examining the results of these trials, the FDA concluded that this regimen was a safe and effective method of medical abortion when employed up through forty-nine days’ gestation. Consequently, the FDA approved the use of mifepristone. The FDA labeling and approval letter indicated that the appropriate treatment regimen was to administer 600 mg of mifepristone orally followed by 0.4 mg of misoprostol administered orally two days later and that mifepristone was not to be administered after forty-nine days’ gestation.

Absent state regulation, once a drug has been approved by the FDA, doctors may prescribe it for indications and in dosages other than those expressly approved by the FDA. This is a widely employed practice known as “off-label” use. Off-label use does not violate federal law or FDA regulations because the FDA regulates the marketing and distribution of drugs in the United States, not the practice of medicine, which is the exclusive realm of individual states. Subsequent to the clinical trials relied upon by the FDA, other trials were conducted experimenting with different possible regimens for administering mifepristone and misoprostol. As a result of this research, an off-label protocol was developed consisting of 200 mg of mifepristone administered orally fol[506]*506lowed one to three days later by 0.8 mg of misoprostol administered vaginally. This regimen is employed up to sixty-three days’ gestation and is known as the Schaff protocol after the doctor whose research primarily led to its development. The Schaff protocol is the method of medical (i.e., non-surgical) abortion recommended by the National Abortion Federation and Planned Parenthood Federation of America and has come to be widely employed across the United States.2

In 2004, the Ohio General Assembly enacted H.B. 126 (“the Act”) to regulate the use of mifepristone in Ohio. Specifically, the Act provides:

No person shall knowingly give, sell, dispense, administer, otherwise provide, or prescribe RU-486 (mifepristone) to another for the purpose of inducing an abortion ... unless the person ... is a physician, the physician satisfies all the criteria established by federal law that a physician must satisfy in order to provide RU-486 (mifepristone) for inducing abortions, and the physician provides the RU-486 (mifepristone) to the other person for the purpose of inducing an abortion in accordance with all provisions of federal law that govern the use of RU-486 (mifepristone) for inducing abortions.

Ohio Rev.Code Ann. § 2919.123(A). The Act defines “federal law” as, “any law, rule, or regulation of the United States or any drug approval letter of the food and drug administration of the United States that governs or regulates the use of RU-486 (mifepristone) for the purpose of inducing abortions.” Ohio Rev.Code Ann. § 2919.123(F). This arguably requires doctors who prescribe mifepristone for the purpose of inducing an abortion to do so only in accordance with the indication, regimen and distribution restrictions approved by the FDA. In other words, the Act arguably prohibits the “off-label” use of mifepristone.

According to the State, the Act was passed because abortion providers in Ohio were openly using the Schaff protocol and “because legislators became aware that several women had died or been severely injured recently as a result of their use of mifepristone.”3 The State further suggests that Ohio legislators concluded that the FDA had only approved one specific protocol for the administration of mifepristone because that was the only safe and effective protocol. Accordingly, the State argues that they banned all other uses of mifepristone to protect Ohio women from unsafe and ineffective mifepristone protocols.

The Act was scheduled to go into effect on September 23, 2004. Dr. Roslyn Kade, Dr. Laszlo Sogor, and various Planned [507]*507Parenthood chapters in Ohio (collectively, “Plaintiffs”) brought this action challenging the constitutionality of the Act on the grounds that it (1) is unconstitutionally vague, (2) violates a patient’s right to bodily integrity by compelling surgery in circumstances where a medical abortion would otherwise be the desired or appropriate treatment, (3) lacks the constitutionally-mandated exception to allow otherwise restricted practices where they are necessary to preserve a woman’s health or life, and (4) imposes an undue burden on a patient’s right to choose abortion by prohibiting a safe and common method of previability abortion. Plaintiffs named as defendants Bob Taft, the Governor of Ohio, and Jim Petro, the Attorney General of Ohio, in their official capacities, and Michael K Allen, as Prosecuting Attorney for Hamilton County, Ohio, and as a representative of a class of all prosecuting attorneys in Ohio (collectively, “the State”).

Before the Act went into effect, Plaintiffs moved for a preliminary injunction. A two-day evidentiary hearing was held in which each side was allotted a total of three hours to present testimony and cross-examine opposing witnesses. Plaintiffs presented the expert testimony of Dr. Eric Sehaff and Dr. Laszlo Sogor. The State presented the testimony of Dr. Susan Crockett. The district court granted the motion for a preliminary injunction on the basis that Plaintiffs had established a strong likelihood of prevailing on their third argument, that the statute needs a health or life exception. The district court did not address the other three arguments. The State timely filed an interlocutory appeal.

II.

Free access — add to your briefcase to read the full text and ask questions with AI

Planned Parenthood Cincinnati Region v. Bob Taft, 444 F.3d 502, 2006 U.S. App. LEXIS 9207, 2006 WL 947302 (6th Cir. 2006).

444 F.3d 502 (Planned Parenthood Cincinnati Region v. Bob Taft) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Untitled Case
E.D. Kentucky, 2026
United States v. Jermaine Kimbrough
138 F.4th 473 (Sixth Circuit, 2025)
L. W. v. Jonathan Skrmetti
83 F.4th 460 (Sixth Circuit, 2023)
GenBioPro, Inc. v. Raynes
S.D. West Virginia, 2023
Planned Parenthood Southwest Ohio Region v. Yost
375 F. Supp. 3d 848 (S.D. Ohio, 2019)
Marc Veasey v. Greg Abbott
830 F.3d 216 (Fifth Circuit, 2016)
Planned Parenthood Southwest Ohio Region v. Dewine
64 F. Supp. 3d 1060 (S.D. Ohio, 2014)
United States v. Randy Sanford
707 F.3d 594 (Sixth Circuit, 2012)
Planned Parenthood Southeast Ohio Region v. DeWine
696 F.3d 490 (Sixth Circuit, 2012)
Hall v. Warden, Lebanon Correctional Institution
662 F.3d 745 (Sixth Circuit, 2011)
Opinion No.
Texas Attorney General Reports, 2010
Untitled Texas Attorney General Opinion
Texas Attorney General Reports, 2010
Planned Parenthood Southwest Ohio Region v. Strickland
331 F. App'x 387 (Sixth Circuit, 2009)
Cordray v. Planned Parenthood Cincinnati Region
2009 Ohio 2972 (Ohio Supreme Court, 2009)
Planned Parenthood Cincinnati Region v. Strickland
531 F.3d 406 (Sixth Circuit, 2008)
Planned Parenthood v. Taft
Sixth Circuit, 2008
White ex rel. Estate of McCullough v. SmithKline Beecham Corp.
538 F. Supp. 2d 1023 (W.D. Michigan, 2008)